571 patients received ≥1 LCM dose; 83 (14.5%) were reported to have epilepsy of cerebrovascular etiology (mean age: 62.6 years [≥65 years: 56.6%]; 50.6% female; mean age at diagnosis: 55.9 years; median baseline [3-month retrospective] seizure frequency/28 days: 2.0). Mean LCM exposure and maintenance dose were 172 days and 289 mg/day, respectively. Treatment-emergent adverse events (TEAE) were reported in 43.4% patients; most commonly (≥5%) fatigue (14.5%) and dizziness (7.2%); 9.6% patients discontinued due to TEAE. Effectiveness was assessed for 71 patients with evaluable seizure records and in-label LCM dosages (up to 400 mg/day). During the last 3 months, 56.3% of patients were seizure-free, 76.1% had a ≥75% reduction in seizure-frequency from baseline, and 81.7% had a ≥50% reduction. The physician-assessed Clinical Global Impression of Change indicated 83.1% patients were improved and 42.3% were “very much improved” compared to baseline.